Mesoblast Limited (MEOBF)

Market Cap	1.93B
Revenue (ttm)	5.67M
Net Income (ttm)	-103.35M
Shares Out	n/a
EPS (ttm)	-0.09
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,000
Average Volume	147,112
Open	0.9650
Previous Close	0.9650
Day's Range	0.9650 - 0.9650
52-Week Range	0.5600 - 5.3400
Beta	1.42
RSI	44.60
Earnings Date	Aug 27, 2025

About Mesoblast

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease and biologic refractory inflammatory bowel disease, as well as Crohn’s disease; and Remestemcel-L, whi...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Employees: 73
• Stock Exchange: OTCMKTS
• Ticker Symbol: MEOBF

Financial Performance

In 2024, Mesoblast's revenue was $5.90 million, a decrease of -21.32% compared to the previous year's $7.50 million. Losses were -$87.96 million, 7.41% more than in 2023.